News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Authors

Derek Choy
Derek Choy

Derek Choy is Co-founder and Chief Product Officer of Aktana

Latest Article

Future-Proofing CRM Investments in Life Sciences: Observations from Dreamforce 2024

a year ago

The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to business operations.

Partha Anbil

Senior advisor to NextGen Invent Corporation

Latest Article

Transforming Drug Safety Through Artificial Intelligence, Large Language Models

8 hours ago

Large language models and natural language processing are reshaping drug safety surveillance by enabling automated adverse event detection, large-scale analysis of regulatory labeling data, and faster, citation-grounded safety assessments while maintaining human oversight and regulatory compliance.

Kenneth Getz, MBA

Executive Director of the Tufts Center for the Study of Drug Development (CSDD)

Latest Article

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

a year ago

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

Advertisement
Advertisement

Trending on PharmExec

1

Eli Lilly Launches Employer Connect Platform Offering Obesity Coverage Options

2

Pharmaceutical Executive Daily: Pharma Industry's AI Adoption

3

The Ongoing Impact of MFN Pricing

4

AI's Inflection Point: Bridging the Adoption and ROI Gap

5

Technological Renaissance: AI’s Integration into the Pharmaceutical Industry

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us